@article {Mitze2020.06.21.20128181, author = {Timo Mitze and Reinhold Kosfeld and Johannes Rode and Klaus W{\"a}lde}, title = {Face Masks Considerably Reduce Covid-19 Cases in Germany}, elocation-id = {2020.06.21.20128181}, year = {2020}, doi = {10.1101/2020.06.21.20128181}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We use the synthetic control method to analyze the effect of face masks on the spread of Covid-19 in Germany. Our identification approach exploits regional variation in the point in time when face masks became compulsory. Depending on the region we analyse, we find that face masks reduced the cumulative number of registered Covid-19 cases between 2.3\% and 13\% over a period of 10 days after they became compulsory. Assessing the credibility of the various estimates, we conclude that face masks reduce the daily growth rate of reported infections by around 40\%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was used to support this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No trials took place on any individual nor was private data gathered on any individual. Data was collected strictly at the country level.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe use the official German statistics on reported Covid-19 cases from the Robert Koch Institute (RKI, 2020). The RKI collects the data from local health authorities and provides updates on a daily basis. Using these data (available via API), we build a balanced panel for 401 NUTS Level 3 regions and 95 days spanning the period from January 28 to May 1, 2020 (38,095 observations). We use the cumulative number of registered Covid-19 cases in each district as main outcome variable. We estimate overall effects for this variable together with disaggregated effects by age groups (persons aged 15-34 years, 35-59 years and 60+ years). As an alternative outcome variable, we also use the cumulative incidence rate. Table 1 shows summary statistics for both variables for our sample period. https://npgeo-corona-npgeo-de.hub.arcgis.com/}, URL = {https://www.medrxiv.org/content/early/2020/06/29/2020.06.21.20128181}, eprint = {https://www.medrxiv.org/content/early/2020/06/29/2020.06.21.20128181.full.pdf}, journal = {medRxiv} }